Last reviewed · How we verify
Pf-06882961 (pf-06882961)
Not specified
Pf-06882961, developed by Pfizer, holds a niche market position with two approved indications but lacks clinical trial data to support further expansion. The drug faces significant competition from alternatives like Semaglutide and Danuglipron tromethamine, which offer daily oral formulations and targeted receptor actions, respectively. A key risk is the requirement for a PD-L1 companion diagnostic, which may limit its broader market adoption. Despite these challenges, the pipeline outlook remains promising as Pfizer continues to explore additional indications and formulations.
At a glance
| Generic name | pf-06882961 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Unfortunately, the mechanism of action for PF-06882961 is not available. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications.
Approved indications
- Non-small cell lung cancer
- Urothelial carcinoma
Common side effects
- Headache
- Nausea
- Diarrhoea
- Vomiting
- Fatigue
- Dizziness
- Constipation
- Hyperglycaemia
- Dyspepsia
- SARS-CoV-2 test positive
- Upper respiratory tract infection
- Abdominal pain
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP3A4 substrates